John H. Kempen
Associate Professor of Ophthalmology
Attending Physician and Surgeon, Department of Ophthalmology/Scheie Eye Institute, Presbyterian Hospital
Attending Physician and Surgeon, Department of Ophthalmology, Hospital of the University of Pennsylvania
Director of Ocular Inflammation Service, Department of Ophthalmology, Scheie Eye Institute, University of Pennsylvania School of Medicine
Director of Ophthalmic Epidemiology and International Ophthalmology , Department of Ophthalmology, University of Pennsylvania School of Medicine
Member, Center for Preventive Ophthalmology and Biostatistics
Member, University of Pennsylvania Graduate Group in Epidemiology and Biostatistics, University of Pennsylvania Graduate Group in Epidemiology and Biostatistics
Senior Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Member, Institute for Translational Medicine and Therapeutics, University of Pennsylvania
Department: Ophthalmology
Contact information
Ocular Inflammation Service
Scheie Eye Institute
51 N. 39th St
Philadelphia, PA 19104
Scheie Eye Institute
51 N. 39th St
Philadelphia, PA 19104
Office: 215-662-8155
Fax: 215-243-4696
Fax: 215-243-4696
Email:
john.kempen@uphs.upenn.edu
john.kempen@uphs.upenn.edu
Graduate Group Affiliations
Publications
Education:
BS (Biological Sciences, with Departmental Honors)
Stanford University, 1988.
MD (Medicine)
School of Medicine, University of California, San Diego, 1992.
MPH (International Health)
School of Hygiene & Public Health, Johns Hopkins University, 1997.
MHS (Biostatistics)
School of Hygiene and Public Health, Johns Hopkins University, 1999.
PhD (Epidemiology)
Bloomberg School of Public Health, Johns Hopkins University, 2001.
Permanent linkBS (Biological Sciences, with Departmental Honors)
Stanford University, 1988.
MD (Medicine)
School of Medicine, University of California, San Diego, 1992.
MPH (International Health)
School of Hygiene & Public Health, Johns Hopkins University, 1997.
MHS (Biostatistics)
School of Hygiene and Public Health, Johns Hopkins University, 1999.
PhD (Epidemiology)
Bloomberg School of Public Health, Johns Hopkins University, 2001.
Description of Research Expertise
Dr. Kempen is well-known nationally and internationally as an expert in ocular inflammatory diseases—such as uveitis, scleritis, and others—as well as ocular complications of AIDS. He is the Director of the Penn Ocular Inflammation Service, and Director of Ophthalmic Epidemiology at the Center for Preventive Ophthalmology and Biostatistics. As an expert epidemiologist, he holds a joint appointment in the Department of Biostatistics & Epidemiology, and the Penn Center for Clinical Epidemiology and Biostatistics.Clinical Research
-Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study (funded by the National Eye Institute): Dr. Kempen is the national Principal Investigator for this study, the first NIH-sponsored multicenter clinical research study in the field of uveitis.
-Multicenter Uveitis Steroid Treatment (MUST) Trial (funded by the National Eye Institute): Dr. Kempen serves as International Vice-Chairman, as well as Director of the Penn Clinical Center enrolling patients in this study.
-Posurdex for Intermediate Uveitis, phase 3 Trial (funded by Allergan): Dr. Kempen directs the Penn clinical center for this study.
-Longitudinal Study of Ocular Complications of AIDS (funded by the National Eye Institute): Dr. Kempen is a co-investigator for this study.
Key words
Uveitis, iritis, pars planitis, panuveitis, sympathetic ophthalmia, choroiditis, retinitis, neuroretinitis, Vogt-Koyanagi-Harada disease, Fuchs’ heterochromic cyclitis, retinal vasculitis, serpiginous retinochoroiditis, birdshot chorioretinitis, immunosuppressive therapy for eye disease, scleritis, orbital inflammatory disease, ocular complications of AIDS, cytomegalovirus retinitis, acute retinal necrosis, infectious retinitis, toxoplasmic retinitis
Description of Itmat Expertise
Dr. Kempen's research focuses on ocular inflammation, ocular complications of AIDS/immunodeficiency, and more generally on the epidemiology and treatment of eye diseasesSelected Publications
Gregory AC 2nd, Kempen JH, Daniel E, Kaçmaz RO, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE; Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Research Group.: Risk Factors for Loss of Visual Acuity among Patients with Uveitis Associated with Juvenile Idiopathic Arthritis: The Systemic Immunosuppressive Therapy for Eye Diseases Ophthalmology 120(1): 186-92, Jan 2013 Notes: Study doi: 10.1016/j.ophtha.2012.07.052. Epub 2012 Oct 11.Mehta S, Hariharan L, Ho AC, Kempen JH: Peripapillary choroidal neovascularization in pars planitis. Journal of Ophthalmic Inflammation and Infection 15;3(1):13. . PubMed PMID: ; PubMed Central PMCID: . 15(3 (1)): 13, Jan 2013 Notes: doi: 10.1186/1869-5760-3-13
Domalpally A, Altaweel MM, Kempen JH, Myers D, Davis JL, Foster CS, Latkany P, Srivastava SK, Stawell RJ, Holbrook JT; For the MUST Trial Research Group: Optical Coherence Tomography Evaluation in the Multicenter Uveitis Steroid Treatment (MUST) Trial Dec;20(6):443-447 Ocul Immunol Inflamm 20(6): 443-447, Dec 2012 Notes: Epub 2012 Nov 19.
Kempen JH*, Sugar EA, Lyon AT, Lewis RA, Jabs DA, Heinemann MH, Dunn JP for the Studies of the Ocular Complications of AIDS: Risk of cataract in persons with cytomegalovirus retinitis and the acquired immune deficiency syndrome. Ophthalmology 119(11): 2343-50, Nov 2012 Notes: *Corresponding author. Epub 2012 Jul 30.
Daniel E, Pistilli M, Pujari SS, Kaçmaz RO, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Kempen JH*: Risk of Hypotony in Non-infectious Uveitis. Ophthalmology 119(11): 2377-85, Nov 2012 Notes: *Corresponding author. Epub 2012 Jul 13.
Udoetuk JD, Dai Y, Ying GS, Daniel E, Gangaputra S, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Kempen JH*: Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology 119(8): 1569-74, Aug 2012 Notes: *Corresponding author. Epub 2012 Apr 6.
Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, Kozak I, Holbrook JT, Jabs DA, Kempen JH for the Multicentre Uveitis Steroid Treatment (MUST) Trial Research Group: The impact of macular edema on visual function in intermediate, posterior and panuveitis. Ocul Immunol Inflamm 20(3): 171-81, Jun 2012 Notes: Epub 2012 Apr 24.
Charkoudian LD, Ying GS, Pujari SS, Gangaputra S, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Kempen JH*: High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm 20(2): 91-9, Apr 2012 Notes: *Corresponding author.
Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, Rao NA, Sen HN, Sugar EA, Thorne JE, Wang RC, Holbrook JT, for the Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group: Associations among visual acuity and vision-and health-related quality of life among patients in the Multicenter Uveitis Steroid Treatment Trial. Investigative Ophthalmology and Visual Science 9;53(3): 1169-76, Mar 2012.
Holbrook JT, Altaweel MM, Kempen JH, Jabs DA: Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial—Lessons for comparative effectiveness trials. Clinical Trials 8: 736-746, Nov 2011 Notes: Epub 2011 Oct 12.